Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programm...
Saved in:
Main Authors: | Ming-xing Wang, Ai-xin Liu, Qing-ming Sun, Wan-hui Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534179/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial
by: Verena Theiler-Schwetz, et al.
Published: (2025-12-01) -
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01) -
Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01) -
DIABETES INSIPIDUS: LITTLE-KNOWN FACTS
by: L. Yu. Morgunov
Published: (2019-06-01) -
A unique coexistence of a plurihormonal pituitary adenoma with granulomatous hypophysitis
by: Sanjiban Patra, et al.
Published: (2023-07-01)